Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option

We present a case of Grade II, well-differentiated rectal neuroendocrine tumor in a 39-year-old patient. Following different sequential treatment modalities, the disease progressed both on metabolic (18F-fluorodeoxyglucose positron emission tomography-computed tomography [18F-FDG PET/CT]) and somato...

Full description

Bibliographic Details
Main Authors: Magdalena Mileva, Zéna Wimana, Patrick Flamen, Ioannis Karfis
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:World Journal of Nuclear Medicine
Subjects:
everolimus
peptide receptor radiotherapy
somatostatin receptor
up-regulation
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2021;volume=20;issue=3;spage=316;epage=318;aulast=Mileva

Internet

http://www.wjnm.org/article.asp?issn=1450-1147;year=2021;volume=20;issue=3;spage=316;epage=318;aulast=Mileva

Similar Items